AstraZeneca to Acquire Alexion for $39B

 AstraZeneca to Acquire Alexion for $39B

AstraZeneca to Acquire Alexion for $39B

Shots:

  • Alexion to receive $60M in cash and 2.1243 ADSs (each ADS represents ½ ordinary share of AstraZeneca) for each Alexion share. The deal values Alexion at $175/ share with a 45% premium to the closing price on Dec 11, 2020
  • Alexion will own ~15% of the combined company. The acquisition will bolster AstraZeneca’s footprints in rare disease and enhance its presence in immunology
  • The duo will work together to build Alexion’s pipeline of 11 molecules across 20+ clinical- programs in rare diseases and beyond. The new company will lead to a WW expansion of Alexion’s portfolio and is expected to deliver double-digit average annual revenue growth through 2025

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: San Diego Business Attorney

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post